Addressing the Cost vs. Quality Conundrum: 3EO Health Receives FDA Emergency Use Authorization, Launches Groundbreaking Point of Care Technology
/
DateOct 02 2023
3EO’s novel technology enables up to 70% savings versus existing point of care molecular tests. Demonstrated strong clinical performance of 95% PPA and 100% NPA.... Read More →